Clinical Trials
6
Active:5
Completed:0
Trial Phases
2 Phases
Phase 1:5
Phase 2:1
Drug Approvals
6
FDA:6
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (83.3%)Phase 2
1 (16.7%)Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections
Phase 2
Recruiting
- Conditions
- Acute Bacterial Skin and Skin Structure Infection
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- Melinta Therapeutics, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT05599295
- Locations
- 🇬🇷
Hippokratio General Hospital of Thessaloniki, Thessaloniki, Greece
🇺🇸Tampa General Hospital, Tampa, Florida, United States
🇺🇸Mount Sinai Beth Israel, New York, New York, United States
Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections
Phase 1
Active, not recruiting
- Conditions
- Gram Positive Bacterial Infections
- Interventions
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Melinta Therapeutics, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT02134301
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Childrens Hospital of Orange County, Orange, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
News
No news found